Phase 4
Completed N=586
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov NCT00541242 ↗Enrolled (actual)
586
Serious AEs
1.8%
Results posted
Oct 2011
Primary outcomePrimary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12 — 21.90; 22.16; -5.64; -4.89 millimeters of mercury (mmHg)
Summary
The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12 |
21.90; 22.16; -5.64; -4.89 | — |
| PRIMARY Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18 |
21.90; 22.16; -5.77; -5.09 | — |
Eligibility Criteria
Inclusion Criteria
- Ocular hypertension or chronic glaucoma
- Patient requires IOP-lowering therapy in both eyes
Exclusion Criteria
- Uncontrolled medical conditions
- Hypersensitivity to study medications
Data sourced from ClinicalTrials.gov (NCT00541242). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.